TISSUE REPAIR LIMITED (TRP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TRP - TISSUE REPAIR LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: N/A
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.27

21 Sep
2023

-0.005

OPEN

$0.27

-1.82%

HIGH

$0.27

25,000

LOW

$0.27

TARGET
$0.79 192.6% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ANP . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TLX . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TRP: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A - 10.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

04/09/2023

1

Speculative Buy

$0.79

192.59%

FY23 results were in line with forecasts and Tissue Repair ended the period with $21.4m in cash, which Morgans deems sufficient to fund the Phase 3 clinical trial in venous leg ulcers.

The trial is expected to start recruitment in Q3 FY24 after delays in manufacturing the active ingredient, explains the analyst.

The Speculative Buy rating and 79c target are unchanged.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -10.10 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -7.80 cents.
Access Stockbroker Research History >

TRP STOCK CHART

FNArena News on TRP

1
FNArena Corporate Results Monitor – 04-09-2023

Sep 04 2023 - Australia
2
FNArena Corporate Results Monitor – 02-09-2022

Sep 02 2022 - Australia
3
FNArena Corporate Results Monitor – 28-02-2022

Feb 28 2022 - Australia

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps
2
Breaking Boundaries: Medical Psychedelics

Aug 21 2023 - Small Caps
3
Momentum Keeps Building For Avita Medical

Aug 15 2023 - Small Caps
4
Dr Boreham’s Crucible: IDT Australia

Aug 14 2023 - Small Caps
5
Treasure Chest: Less Smooth Road Ahead For CSL

Aug 01 2023 - Treasure Chest
6
Dr Boreham’s Crucible: Telix Pharmaceuticals

Jul 31 2023 - Small Caps
7
Dr Boreham’s Crucible: Arovella Therapeutics

Jul 17 2023 - Small Caps
8
Dr Boreham’s Crucible: PolyNovo

Jul 06 2023 - Small Caps
9
CSL Disappoints But Brokers Retain The Faith

Jun 15 2023 - Australia
10
Dr Boreham’s Crucible: Dimerix

Jun 07 2023 - Small Caps